GB1413401A - Influenza vaccine - Google Patents

Influenza vaccine

Info

Publication number
GB1413401A
GB1413401A GB4469073A GB4469073A GB1413401A GB 1413401 A GB1413401 A GB 1413401A GB 4469073 A GB4469073 A GB 4469073A GB 4469073 A GB4469073 A GB 4469073A GB 1413401 A GB1413401 A GB 1413401A
Authority
GB
United Kingdom
Prior art keywords
virus
reactivity
recombinant
antigen
cross
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB4469073A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of GB1413401A publication Critical patent/GB1413401A/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1413401 Influenza vaccines MOUNT SINAI SCHOOL OF MEDICINE OF THE CITY UNIVERSITY OF NEW YORK 24 Sept 1973 [25 Sept1972] 44690/73 Heading A5B [Also in Division C6] A recombinant, antigenically hybridised virus contains a haemagglutinin antigen having substantially no cross-reactivity with a challenge influenza virus and a neuraminidase antigen having substantial cross-reactivity with the challenge influenza virus, the recombinant being derived from viruses which are non- neurovirulent. The neuraminidase antigen may be derived from a subtype of Type A, B and C influenza viruses or from the Hong Kong variant. The haemagglutinin antigen may be derived from A/equine 1 virus. A recombinant virus H/eq 1/N2 which is effective against the Hong Kong variant can be formulated by recombining an Ao influenza virus e.g. Ao/PR 8/34 (HON 1) with the Hong Kong variant e.g. HK/Aichi/68 (H3N2) to form hybrid recombinants, some of which contain haemagglutinin and neuraminidase antigens which both have cross-reactivity with the type of influenza virus against which the viral vaccine is to be effective. This portion of the population of the first progeny is then recombined, after isolation, with another virus such as A/eq 1/56 (Heq 1 Neq 1 ) with a haemagglutinin antigen having substantially no cross-reactivity with the challenge influenza virus. The vaccine is prepared by adding 500-2000 chick-cell agglutinating units of the recombinant, antigenically hybridised virus to 1 ml or buffered saline, optionally including a mineral oil adjuvant.
GB4469073A 1972-09-25 1973-09-24 Influenza vaccine Expired GB1413401A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29179772A 1972-09-25 1972-09-25

Publications (1)

Publication Number Publication Date
GB1413401A true GB1413401A (en) 1975-11-12

Family

ID=23121873

Family Applications (1)

Application Number Title Priority Date Filing Date
GB4469073A Expired GB1413401A (en) 1972-09-25 1973-09-24 Influenza vaccine

Country Status (3)

Country Link
CA (1) CA1030449A (en)
GB (1) GB1413401A (en)
PH (1) PH12704A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113665A2 (en) * 1983-01-08 1984-07-18 The Wellcome Foundation Limited Novel viruses and vaccines
WO2007065967A1 (en) * 2005-12-05 2007-06-14 Remedal Oy A vaccine suitable for use against the next influenza a pandemia

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113665A2 (en) * 1983-01-08 1984-07-18 The Wellcome Foundation Limited Novel viruses and vaccines
EP0113665A3 (en) * 1983-01-08 1986-12-30 The Wellcome Foundation Limited Novel viruses and vaccines
WO2007065967A1 (en) * 2005-12-05 2007-06-14 Remedal Oy A vaccine suitable for use against the next influenza a pandemia

Also Published As

Publication number Publication date
CA1030449A (en) 1978-05-02
PH12704A (en) 1979-07-20
AU6067573A (en) 1975-03-27

Similar Documents

Publication Publication Date Title
Johansson et al. Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition
MY103182A (en) Vaccines against acquired immune deficiency syndrome.
DK1618889T3 (en) Influenza vaccine
JP2011504486A5 (en)
Ogra et al. Clinical and immunologic evaluation of neuraminidasespecific influenza A virus vaccine in humans
DE69628834D1 (en) VIRUS VACCINE
HU9401056D0 (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
GB8300467D0 (en) Equine influenza
IL130075A0 (en) A vaccine for eliciting an immune response to an antigen in an animal
GB1292803A (en) Improvements relating to the production of antigens
Uchida Development of a cytotoxic T‐lymphocyte‐based, broadly protective influenza vaccine
Armerding et al. Evaluation of live and inactivated influenza A virus vaccines in a mouse model
GB1413401A (en) Influenza vaccine
Schulman et al. The antigenic relationship of the neuraminidase of Hong Kong virus to that of other human strains of influenza A virus
Laver et al. Diversity of the antibody response to the different antigenic determinants on the hemagglutinin subunits of influenza viruses
Hauge et al. Quality and kinetics of the antibody response in mice after three different low-dose influenza virus vaccination strategies
GB1256457A (en) Diethylaminoethyldextran (deae-d) as adjuvant for vaccines for active immunisation
ES432385A1 (en) Influenza vaccines
NO175846C (en) Method of obtaining an immunogen
Kasel et al. Effect of influenza anti-neuraminidase antibody on virus neutralization
GB1099555A (en) Process for the manufacture of influenza vaccines
McLaren et al. Immunity to influenza in ferrets: XII. Immunization of ferrets with TNBP-split influenza virus vaccine
Kikuta et al. Enhancement of DTH response by cholera toxin B subunit inoculated intranasally together with influenza HA vaccine
Stuart-Harris Immunity to influenza
RU2099086C1 (en) Method for prophylaxis of influenza in children by administering live influenza vaccine

Legal Events

Date Code Title Description
PS Patent sealed
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19920924